Format

Send to

Choose Destination
Neurobiol Dis. 2012 Jun;46(3):625-34. doi: 10.1016/j.nbd.2012.02.012. Epub 2012 Mar 5.

8OHdG as a marker for Huntington disease progression.

Collaborators (311)

Wassink T, Cross S, Doucette N, Kimble M, Ryan P, Wood J, Epping EA, Beglinger LJ, Chiu E, Yastrubetskaya O, Preston J, Goh A, Fonseka C, Ronsisvalle L, Chua P, Komiti A, Raymond L, Dar Santos R, Decolongon J, Rosenblatt A, Ross CA, Shpritz B, Welsh C, Mallonee WM, Suter G, Addison J, Samii A, Macaraeg A, Jones R, Wood-Siverio C, Factor SA, Testa C, Barker RA, Mason S, Goodman A, Swain R, DiPietro A, McCusker E, Griffith J, Loy C, Gunn D, Stewart L, Landwehrmeyer BG, Orth M, Süβmuth S, Barth K, Trautmann S, Quaid K, Wesson M, Wojcieszek J, Guttman M, Sheinberg A, Karmalkar I, Perlman S, Johnson A, Geschwind MD, Gooblar J, Kang G, Warner T, Burrows M, Novak M, Andrews T, Rosser E, Tabrizi S, Rosser A, Price K, Hunt S, Marshall F, Chesire A, Wodarski M, Hickey C, Suchowersky O, Furtado S, Klimek ML, Panegyres P, Vuletich E, Andrew S, Zombor R, Perlmutter J, Barton S, Schmidt A, Miedzybrodzka Z, Simpson SA, Rae D, D'Alessandro M, Craufurd D, Fullam R, Howard E, Mazzoni P, Marder K, Wasserman P, Kumar R, Erickson D, Wheelock V, Tempkin T, Mans N, Baynes K, Jankovic J, Hunter C, Ondo W, de Yebenes JG, Garde MB, Fatas M, Martinez-Descales A, Martin W, King P, Sran S, Ahmed A, Rao S, Reece C, Zimbelman J, Bea A, Newman E, Bura A, Paulsen J, Epping EA, Johnson H, Smith MM, Williams J, Beglinger L, Mills J, Aylward E, Biglan K, Leavitt B, MacDonald M, Nance M, Erwin C, Leavitt BR, Hayden M, DiDonato S, Evans K, Matson WR, Peterson A, Tabrizi S, Borowsky B, Juhl A, Mills J, Weir D, Vonsattell JP, Moskowitz C, Leserman A, Schaul L, Vik S, Harrington D, Castillo G, Morison J, Reed J, Diaz M, Dobbins I, Hershey T, Foster E, Moore D, Westervelt H, Davis J, Tremont G, Smith MM, Moser DJ, Beglinger LJ, Rowe K, Theriault D, Gehl C, Matheson K, Siedlecki K, Van Walsem M, Bonner S, Elias G, Faust M, Borowski B, Carlozzi N, Duff K, Georgiou-Karistianis N, Stout J, Lange H, Papp K, Williams J, Beglinger LJ, Leserman A, Ro E, Clark LA, Downing N, Laing J, Rees K, Vik S, Ready R, Vaccarino A, Farias S, Carlozzi N, Gehl C, MacDonald M, Gusella J, Myers R, Hayden M, Wassink T, Epping EA, Juhl A, Mills J, Wang K, Miedzybrodzka Z, Ross C, Pierson R, Jones K, Marietta J, McDowell W, Harris G, Kim EY, Johnson H, Wassink T, Ashburner J, Potkin S, Toga A, Aylward E, Axelson E, Ross CA, Miller M, Reading S, Beg MF, Magnotta VA, Helmer K, Lim K, Lowe M, Mori S, Song A, Turner J, Rao S, Beall E, Koenig K, Phillips M, Reece C, Zimbelman J, Bryant A, Biglan K, Marder K, Corey-Bloom J, Geschwind M, Reilmann R, Unds Z, Juhl A, Epping EA, Downing N, Fiedorowicz J, Robinson R, Smith MM, Beglinger L, Mills J, Rees K, Ruggle A, Vik S, Williams J, Liu D, Moser D, Rowe K, Anderson K, Craufurd D, Groves M, Vaccarino A, Evans K, Rickards H, van Duijn E, Antonijevic I, Giuliano J, Chua P, Quaid K, Mills J, Liu D, Long J, Lu W, Lourens S, Zhang Y, Nance M, Leserman A, Doucette N, Kimble M, Ryan P, Thumma K, Waterman E, Hinkel J, Erwin C, Epping EA, Williams J, Doucette N, Leserman A, Mills J, Schaul L, Vik S, Nance M, Hughes L, Johnson H, Connell RJ, Pease K, Rogers B, Smith J, Wu S, Zschiegner R, Carney E, McKirgan B, Scully M, Wyse R, Bockholt J, Werling-Witkoske C, Anderson K, Rapp J, Dudler A, Schumacher J, Thompson S, Davis L, Henneberry M, Ennis G, Vik S, Blanchard S, Montross K, Danzer P.

Author information

1
Department of Psychiatry, The University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA. jeffrey-long@uiowa.edu

Abstract

Leukocyte 8-hydroxydeoxyguanosine (8OHdG) is an indicator of oxidative stress, impaired metabolism, and mitochondrial dysfunction, features that have been implicated in Huntington disease (HD). Increased levels of 8OHdG have been reported in the caudate, parietal cortex, and peripherally in the serum and leukocytes, in patients diagnosed with HD. However, little is known about levels in prodromal patients and changes that might occur as the disease progresses. To address these issues, 8OHdG was tracked over time for a subset of participants enrolled in the PREDICT-HD study. Participants were stratified into four groups based on proximity to HD diagnosis at study entry: Controls (gene-negative individuals), Low (low probability of near-future diagnosis), Medium, and High. Blood samples were analyzed using Liquid Chromatography Electrochemical Array, and for comparison purposes, a separate cross-sectional sample was analyzed using liquid chromatography coupled with multiple-reaction-monitoring mass spectrometry. Longitudinal data analysis showed that initial status (at study entry) and annual rate of change varied as a function of proximity group, adjusting for sex, education, age at study entry, and site effects. Overall levels were lowest for the Control group and highest for the High group, and the rate of increase varied in a similar manner. The finding that 8OHdG concentrations increased as a function of proximity to projected disease diagnosis and duration indicates support for the continued assessment of 8OHdG as a robust clinical HD biomarker.

PMID:
22414782
PMCID:
PMC3784019
DOI:
10.1016/j.nbd.2012.02.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center